Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Jorge AparicioAnna C Virgili ManriqueJaume CapdevilaFélix Muñoz BozaPatricia GalvánPaula RichartHelena OliveresDavid PáezJorge HernandoSara SerranoRuth VeraXavier Hernandez-YagüeRafael Álvarez GallegoM Carmen Riesco-MartinezXavier García de AlbenizJoan MaurelPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)
The BEYOND study suggests a meaningful benefit of P-FOLFIRI beyond progression to P-FOLFOX in metastatic colorectal cancer patients with WT RAS status selected by LB. This strategy deserves further investigation.